All News
Why Rheumatologists Should Do Better Vaccinating this Flu Season
It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al.
Read Article
Jak Inhibition May Ameliorate Pruritus
Interleukin-4 has been shown to activate sensory neurons involved in pruritus, and that inhibition of IL-4 with Jak inhibition significantly alleviates itching.
Read Article
Past Infection, Lung Disease Raise Risk for Myopathy
Infections and noninfectious pulmonary disease were associated with an increased risk for idiopathic inflammatory myopathies (IIM), a Swedish study found.
Read Article
Biologic Use in Adult-Onset Still's Disease
Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.
Read Article
8 September 2017: The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.
Read Article
Hugo E. Jasin, MD (1933-2017)
Hugo E. Jasin, M.D., a long-time faculty member at The University of Texas Southwestern Medeical Center and the University of Arkansas College of Medicine, passed away on August 24th, at the age of 84 years.
Read Article
New Recommendations on Biosimilar Use
The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.
Read Article
Rheumatoid Arthritis Augments Cardiovascular Risk
A large multi-center study of cardiovascular (CV) risk factors in rheumatoid arthritis (RA) has shown, after nearly 6 years follow-up, more CV events in males than females (21% vs. 11%, respectively) and that RA itself accounts for 30% of the attributable CV risk.
Read Article
Psoriasis Doubles Mortality Risk
Noe and colleagues have reported in the Journal of Investigative Dermatology that by estimating the extent of skin involvement in psoriasis (%BSA) they may assess future mortality risk.
Read Article
New EULAR Guidelines for Ultrasound Use
In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.
Read Article
Do Rheumatologists Use ACR/EULAR Guidance on Rheumatoid Arthritis? “Live Vote” Results
The June 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists and patients about how they diagnose and treat rheumatoid arthritis (RA) and whether they rely on newer diagnostic criteria and management guidelines propagated by the American College of Rheumatology (ACR).
Read Article
Increasing Deaths and Breaking Bad with Fentanyl
Opioid overdose deaths quadrupled from 1999 to 2015 and accounted for 63% of drug overdose deaths in the United States in 2015. During 2010–2015, heroin overdose deaths quadrupled from 3,036 to 12,989, with heroin and illicitly manufactured fentanyl (IMF) as likely contributors to this trend.
Read Article
1 September 2017: The RheumNow Week in Review
This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections: HBV, shingles and mortality of septic arthritis.
Read Article
What Can 30 Years of Rheumatic Disease Research Tell Us About the Future?
As a practicing rheumatologist for more than 30 years, I can recall a time – just a couple of decades ago – when waiting rooms were full of patients in wheelchairs, debilitated and in pain from rheumatoid arthritis (RA) and other related conditions.
Read Article
DSB Reports & Updates – August 2017
This Drug Safety Bulletin address FDA delay of baricitinib, etanercept effective at room temperature, Consumer Reports features on drug safety, no association between Alzheimer's and PPIs, AHRQ review of opioid drug safety, FDA safety abeling changes, drug shortages and more.
Read Article
Canakinumab Patients have Lower Risk of Lung Cancer
The CANTOS trial has shown that interleukin 1β inhibition by Canakinumab (CAN) resulted not only in a reduction of cardiovascular deaths but also significantly decreased the incidence and death from lung cancer.
Read Article
Idiopathic Inflammatory Myopathy Quadruples Death Risk
A Swedish population-based study found a nearly fourfold greater risk of all-cause mortality in idiopathic inflammatory myopathy (IIM) patients compared with the general population.
Read Article
Turnabout for Baricitinib
Eli Lilly and Company and Incyte Corporation announced today that, after discussions with the U.S. Food and Drug Administration in late August 2017, Lilly will resubmit a revised New Drug Application for baricitinib before the end of January 2018. The resubmission package will include new safety and efficacy data.
Read Article
Patient Recordings of Visits May be Legal
The current issue of JAMA reviews the rising practice of patient recording of medical visits and their legality.
Read Article
Shingles Vaccine Studies in A&R
The current issue of Arthritis & Rheumatology features an editorial and two novel articles on the herpes zoster vaccine.
Read Article